Biogen (BIIB) Call Leaves Tons of Questions, Priority Review Voucher Comment is Negative - Mizuho

Go back to Biogen (BIIB) Call Leaves Tons of Questions, Priority Review Voucher Comment is Negative - Mizuho

Biogen (BIIB) CFO Transition Raises Questions Considering Pipeline - Mizuho Securities

July 22, 2020 7:10 AM EDT

Mizuho Securities analyst Salim Syed reiterated a Neutral rating and $316.00 price target on Biogen (NASDAQ: BIIB) after the company announced that its CFO, Jeff Capello, is leaving. The transition occurs at a strange time raising numerous questions.

The analyst stated "Capello's... More

Biogen (BIIB) Tops Q2 EPS by $2.22, Guidance Beats

July 22, 2020 6:52 AM EDT

Biogen (NASDAQ: BIIB) reported Q2 EPS of $10.26, $2.22 better than the analyst estimate of $8.04. Revenue for the quarter came in at $3.68 billion versus the consensus estimate of $3.44 billion.

GUIDANCE:

Biogen sees FY2020 EPS of $34.00-$36.00, versus the consensus of $32.96. Biogen sees... More

Biogen (BIIB) CFO Jeffrey Capello Steps Down, Michael McDonnell Named to Position

July 22, 2020 6:32 AM EDT

Biogen (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020. McDonnell joins Biogen from IQVIA (NYSE: IQV), where he is Executive Vice President and Chief Financial Officer. At Biogen, McDonnell will lead the global finance function and operations, the Companys shared services center, information technology and investor relations groups. He will report directly to Biogens Chief Executive Officer Michel Vounatsos, and will be based in Cambridge, Massachusetts.

McDonnell brings an extensive background in... More